News

During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL

Dr Dhingra is currently heading KAPital Consulting, a company engaged in helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of the advances in oncology.

The agreement will involve co-operation in joint marketing and promotional activities and the integration of PreViser analytic technology into MacPractice DDS 3.6, making MacPractice the only native Mac-compatible

This agreement is expected to provide the physicians greater choice and flexibility in offering patients the newest isotope available. According to IsoRay, the Cesium-131 seed offers a significantly

According to Cordex, the amendment addresses written comments recently received from the FDA in response to the company’s initial special protocol assessment (SPA) submission to the FDA in

The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop

The CE mark makes it possible for cancer treatment centers to begin ordering, installing, and using the Varian proton therapy system in regions where CE mark is required

The Phase IIa study is designed to assess the efficacy, safety, tolerability and pharmacokinetics of ALKS 27 in approximately 24 patients with chronic obstructive pulmonary disease (COPD). In

Net loss for the fourth quarter of 2008 includes total stock-based compensation expense of $3.7 million, compared to $1.8 million for the fourth quarter of 2007. For the